Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153330 · ClinicalTrials.gov registry record · Phase 1
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 study, sponsored by Biomea Fusion.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT05153330 is a Phase 1 study that was terminated before completion, run by Biomea Fusion. The registered enrollment target is 55 participants.
The verdict
NCT05153330, a Phase 1 study, was terminated before completion, sponsored by Biomea Fusion.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
Interventions
- DRUG BMF-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2025-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153330
The ClinicalTrials.gov registry entry for NCT05153330 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomea Fusion, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMF-219 is the first listed.
NCT05153330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05153330 about?
NCT05153330 is a clinical study titled "Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL". A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
What is the current status of trial NCT05153330?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2022-01-24. Estimated completion is 2025-05-02.
What interventions are being tested in trial NCT05153330?
The interventions under investigation include: BMF-219 (DRUG).
Who is sponsoring clinical trial NCT05153330?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.